Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jörg Velker is active.

Publication


Featured researches published by Jörg Velker.


Journal of Medicinal Chemistry | 2013

Novel S1P1 Receptor Agonists – Part 1: From Pyrazoles to Thiophenes

Martin Bolli; Claus Müller; Boris Mathys; Stefan Abele; Magdalena Birker; Roberto Bravo; Daniel Bur; Patrick Hess; Christopher Kohl; David Lehmann; Oliver Nayler; Markus Rey; Solange Meyer; Michael Scherz; Gunther Schmidt; Beat Steiner; Alexander Treiber; Jörg Velker; Thomas Weller

From a high-throughput screening campaign aiming at the identification of novel S1P1 receptor agonists, the pyrazole derivative 2 emerged as a hit structure. Medicinal chemistry efforts focused not only on improving the potency of the compound but in particular also on resolving its inherent instability issue. This led to the discovery of novel bicyclo[3.1.0]hexane fused thiophene derivatives. Compounds with high affinity and selectivity for S1P1 efficiently reducing the blood lymphocyte count in the rat were identified. For instance, compound 85 showed EC50 values of 7 and 2880 nM on S1P1 and S1P3, respectively, had favorable pharmacokinetic properties in rat and dog, distributed well into brain tissue, and efficiently and dose dependently reduced the blood lymphocyte count in the rat. After oral administration to spontaneously hypertensive rats, the S1P1 selective compound 85 showed no effect on mean arterial blood pressure and affected the heart rate during the wake phase of the animals only.


Journal of Medicinal Chemistry | 2014

Novel S1P1 Receptor Agonists - Part 2: From Bicyclo[3.1.0]hexane-Fused Thiophenes to Isobutyl Substituted Thiophenes

Martin Bolli; Jörg Velker; Claus Müller; Boris Mathys; Magdalena Birker; Roberto Bravo; Daniel Bur; Ruben de Kanter; Patrick Hess; Christopher Kohl; David Lehmann; Solange Meyer; Oliver Nayler; Markus Rey; Michael Scherz; Beat Steiner

Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P1 receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene head. In a first step the bicyclohexane moiety could be replaced by a simpler, less rigid cyclohexane ring without compromising the S1P receptor affinity profile of these novel compounds. In a second step, the thiophene head was simplified even further by replacing the cyclohexane ring with an isobutyl group attached either to position 4 or position 5 of the thiophene. These structurally much simpler headgroups again furnished potent and selective S1P1 agonists (e.g., 87), which efficiently and dose dependently reduced the number of circulating lymphocytes upon oral administration to male Wistar rats. For several compounds discussed in this report lymphatic transport is an important route of absorption that may offer opportunities for a tissue targeted approach with minimal plasma exposure.


Journal of Pharmacology and Experimental Therapeutics | 2004

Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

Martine Clozel; Christophe Binkert; Magdalena Birker-Robaczewska; Céline Boukhadra; Shuang-Shuang Ding; Walter Fischli; Patrick Hess; Boris Mathys; Keith Morrison; Celia Muller; Claus Müller; Oliver Nayler; Changbin Qiu; Markus Rey; Michael Scherz; Jörg Velker; Thomas Weller; Jian-Fei Xi; Patrick Ziltener


Archive | 2006

NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS

Martin Bolli; David Lehmann; Boris Mathys; Claus Mueller; Oliver Nayler; Jörg Velker; Thomas Weller


Journal of Medicinal Chemistry | 2014

Novel S1P1 Receptor Agonists − Part 3: From Thiophenes to Pyridines

Martin Bolli; Stefan Abele; Magdalena Birker; Roberto Bravo; Daniel Bur; Ruben de Kanter; Christopher Kohl; Julien Grimont; Patrick Hess; Cyrille Lescop; Boris Mathys; Claus Müller; Oliver Nayler; Markus Rey; Michael Scherz; Gunther Schmidt; Jürgen Seifert; Beat Steiner; Jörg Velker; Thomas Weller


Archive | 2008

Pyridine derivatives as S1P1/EDG1 receptor modulators

Martin Bolli; Cyrille Lescop; Boris Mathys; Claus Mueller; Oliver Nayler; Beat Steiner; Jörg Velker


Archive | 2004

PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS

Boris Mathys; Claus Müller; Michael Scherz; Thomas Weller; Martine Clozel; Jörg Velker; Daniel Bur


Archive | 2007

Thiophene derivatives as S1P1/EDGE1 receptor agonists

Martin Bolli; David Lehmann; Boris Mathys; Claus Mueller; Oliver Nayler; Beat Steiner; Jörg Velker


European Journal of Medicinal Chemistry | 2016

Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines

Martin Bolli; Cyrille Lescop; Magdalena Birker; Ruben de Kanter; Patrick Hess; Christopher Kohl; Oliver Nayler; Markus Rey; Patrick Sieber; Jörg Velker; Thomas Weller; Beat Steiner


Archive | 2004

Piperazine-alkyl-ureido derivatives

Hamed Aissaoui; Christoph Binkert; Martine Clozel; Boris Mathys; Claus Müller; Oliver Nayler; Michael Scherz; Jörg Velker; Thomas Weller

Collaboration


Dive into the Jörg Velker's collaboration.

Researchain Logo
Decentralizing Knowledge